Latest
07:39
[ DAIDO GROUP (00544.HK): Subscription for New Shares Under General Mandate to Raise HK$10 Million ] NewTimeSpace News: DAIDO GROUP announced on 30 July that the Company has entered into a subscription agreement with the subscriber. It proposes to allot and issue 10 million new shares at HK$1 per share, raising gross and net proceeds of approximately HK$10 million, which will be used for the Group’s general working capital.
Tag:
DAIDO GROUP00544.HK
21:56
[ Mininglamp-W (02718.HK): Proposes RMB859 Million Acquisition of 19.07% Stake in Pulin Software; Redirects RMB450 Million IPO Proceeds for Strategic M&A ] NewTimeSpace News: Mininglamp Technology announced that its indirect wholly-owned subsidiary agreed to acquire a 19.07% stake in Shenzhen-listed Pulin Software for approximately RMB 859 million at RMB 11.38 per share, with Wu Minghui to become the actual controller upon completion; the Sellers provided earnings and asset recovery commitments. Concurrently, the board approved redirecting RMB 450 million of unused IPO proceeds to strategic M&A, with approximately RMB 429.45 million earmarked for 50% of the acquisition cost. The transaction constitutes a discloseable transaction.
Tag:
MININGLAMP-W02718.HK
21:33
[ CSPC Pharmaceutical (01093.HK): SYH2062 Hypertension Phase II Trial Initiated at First China Site; CRB-701 FDA Cleared for Pivotal OPSCC Trial ] NewTimeSpace News: CSPC Pharmaceutical announced that its siRNA antihypertensive candidate SYH2062 has initiated Phase II trials in China for adult primary hypertension, while its Nectin-4-targeting ADC CRB-701, out-licensed to Corbus, received FDA clearance for the registrational TEMPO-1 trial in second-line oropharyngeal squamous cell carcinoma with enrollment expected in Q3 2026, following two prior Fast Track designations.
Tag:
CSPC PHARMA01093.HK
19:28